Voelkel, Vinzenz and Gerken, Michael and Kleihues-van Tol, Kees and Schoffer, Olaf and Bierbaum, Veronika and Bobeth, Christoph and Roessler, Martin and Blum, Torsten and Griesinger, Frank and Guenster, Christian and Hansinger, Judith and Schmitt, Jochen and Klinkhammer-Schalke, Monika (2025) Long-term survival after treatment in certified lung cancer centers and not certified hospitals: Results of a large German cohort study using clinical routine data = Langzeitüberleben nach Behandlung in zertifizierten Lungenkrebszentren und nicht zertifizierten Krankenhäusern: Ergebnisse einer großen deutschen Kohortenstudie mit klinischen Routinedaten. GESUNDHEITSWESEN, 87 (S03). S373-S382. ISSN 0941-3790, 1439-4421
Full text not available from this repository. (Request a copy)Abstract
Objective Lung cancer represents the second most frequent tumor entity worldwide with an increasing number of patients treated in specialized centers. The aim of the WiZen study was to find out whether treatment at hospitals certified by the German Cancer Society (GCS) was associated with long-term survival benefits. Methods Data for this cohort study was derived from the largest German statutory health insurance (SHI) AOK, four regional population-based clinical cancer registries (CCR), and standardized hospital quality reports. The analyses were based on 173,999 incident lung cancer patients in the SHI dataset and 35,702 patients in the CCR dataset who received primary treatment for lung cancer (ICD-10-GM C33, C34, D38.1) between 2009 and 2017. Results Distributions of age, sex, comorbidities, and most tumor characteristics were similar among patients treated in certified and non-certified hospitals. The Kaplan-Meier estimator for 5-year overall survival was 28.0% for patients from certified and 16.9% from non-certified hospitals (SHI data; CCR data: 21.4% vs. 13.6%). Cox-regression adjusting for relevant confounders yielded hazard ratios of 0.97 (SHI data; 95%CI 0.94, 1.00) and 0.85 (CCR data; 95%CI 0.82, 0.88) for all-cause mortality. The adjusted hazard ratio for recurrence-free survival (CCR data, UICC stage I-III, R0 only) was 0.82 (95%CI 0.75, 0.90). Conclusions The presented analyses show that treatment in certified lung cancer centers is associated with relevant survival benefits and should therefore be supported.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | VOLUME; BREAST; CARE; Certified cancer center; specialized treatment; lung cancer; cohort study; survival; quality of cancer care; Certified cancer center; specialized treatment; lung cancer; cohort study; survival; quality of cancer care |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 07 May 2026 08:43 |
| Last Modified: | 07 May 2026 08:43 |
| URI: | https://pred.uni-regensburg.de/id/eprint/66535 |
Actions (login required)
 |
View Item |
